AU2022328272A1 - Treatment of hair loss disorders with deuterated jak inhibitors - Google Patents

Treatment of hair loss disorders with deuterated jak inhibitors Download PDF

Info

Publication number
AU2022328272A1
AU2022328272A1 AU2022328272A AU2022328272A AU2022328272A1 AU 2022328272 A1 AU2022328272 A1 AU 2022328272A1 AU 2022328272 A AU2022328272 A AU 2022328272A AU 2022328272 A AU2022328272 A AU 2022328272A AU 2022328272 A1 AU2022328272 A1 AU 2022328272A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
day
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022328272A
Other languages
English (en)
Inventor
Christopher L. Brummel
James V. CASSELLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Sun Pharmaceutical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Inc filed Critical Sun Pharmaceutical Industries Inc
Publication of AU2022328272A1 publication Critical patent/AU2022328272A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022328272A 2021-08-11 2022-08-11 Treatment of hair loss disorders with deuterated jak inhibitors Pending AU2022328272A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163232107P 2021-08-11 2021-08-11
US63/232,107 2021-08-11
PCT/US2022/040115 WO2023018904A1 (en) 2021-08-11 2022-08-11 Treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
AU2022328272A1 true AU2022328272A1 (en) 2024-02-22

Family

ID=83151848

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022328272A Pending AU2022328272A1 (en) 2021-08-11 2022-08-11 Treatment of hair loss disorders with deuterated jak inhibitors

Country Status (7)

Country Link
US (2) US12285432B2 (https=)
EP (1) EP4384175A1 (https=)
JP (1) JP2024531188A (https=)
CN (1) CN118159272A (https=)
AU (1) AU2022328272A1 (https=)
CA (1) CA3228505A1 (https=)
WO (1) WO2023018904A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021372512A1 (en) * 2020-10-28 2023-06-22 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CA3228505A1 (en) 2021-08-11 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US20260027120A1 (en) * 2024-07-25 2026-01-29 Sun Pharmaceutical Industries, Inc. Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CN1255185C (zh) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
MX2007003731A (es) 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
US20070202077A1 (en) * 2005-12-02 2007-08-30 Brodsky Robert A Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
TWI720517B (zh) 2009-01-15 2021-03-01 美商英塞特公司 製造ｊａｋ抑制劑之方法及相關中間化合物
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
HRP20250965T1 (hr) * 2012-06-15 2025-10-10 Sun Pharmaceutical Industries, Inc. Deuterirani derivati ruksolitiniba
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
KR20160117596A (ko) 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
ES2988629T3 (es) * 2016-05-04 2024-11-21 Sun Pharmaceutical Ind Inc Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados
AU2020219797B2 (en) 2019-02-06 2025-10-16 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched jak inhibitors
CA3228505A1 (en) 2021-08-11 2023-02-16 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors

Also Published As

Publication number Publication date
JP2024531188A (ja) 2024-08-29
US20250275979A1 (en) 2025-09-04
CA3228505A1 (en) 2023-02-16
EP4384175A1 (en) 2024-06-19
WO2023018904A1 (en) 2023-02-16
CN118159272A (zh) 2024-06-07
US12285432B2 (en) 2025-04-29
US20240058345A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
US12285432B2 (en) Treatment of hair loss disorders with deuterated JAK inhibitors
US20240423986A1 (en) Treatment of hair loss disorders with deuterated jak inhibitors
US11919907B2 (en) Deuterated JAK inhibitor and uses thereof
US20250275977A1 (en) Dosage regimens for treatment with deuterated jak inhibitors
HK40112813A (en) Treatment of hair loss disorders with deuterated jak inhibitors
OA22110A (en) Dosage Regimens For Treatment With Deuterated Jak Inhibitors.
WO2026020108A1 (en) Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors
EA052710B1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak
HK40002100A (en) Treatment of hair loss disorders with deuterated jak inhibitors